Abstract
Purpose :
To determine survival disparities by months from diagnosis to treatment in cases of orbital RMS.
Methods :
Analysis of the Surveillance, Epidemiology, and End Results Program, 17 registries database, was executed for mixed-type, embryonal, spindle cell, and alveolar RMS primary to the orbit diagnosed between 2000 and 2019 . Relevant demographic and clinical variables were extracted for analysis. Cox proportional hazards models were performed to characterize the influence of length of time (in months) from diagnosis to initial treatment on all-cause survival. RMS cases originating in the orbit were included; cases originating elsewhere were excluded. Statistical significance was defined as p<0.05.
Results :
Orbital RMS was observed in 141 total cases. Most patients were diagnosed before 18 years of age (N=129, 91%). Most patients received radiation therapy (N=120, 93%); beam radiation was most common type of radiation received (N=115, 89%). Nearly half of patients did not receive any surgery (N=65, 46%), N=35 cases (25%) received an excisional biopsy. Most cases received chemotherapy (N=132, 95%). Within the multivariate analysis, cases receiving initial treatment three months post-diagnosis experienced a significantly increased all-cause mortality relative to cases receiving treatment within 30 days (HR=10.58.526, 95% CI 5.707 - 196331.468, p=0.009) (Figure 1).
Conclusions :
Orbital RMS is classically considered a rapidly growing tumor. Our national analysis highlights time to treatment as an important clinical metric in all-cause mortality. Additional studies should be performed to confirm these findings.
This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.